[go: up one dir, main page]

MX2014014708A - Nuevos compuestos biciclicos de tiofenilamida. - Google Patents

Nuevos compuestos biciclicos de tiofenilamida.

Info

Publication number
MX2014014708A
MX2014014708A MX2014014708A MX2014014708A MX2014014708A MX 2014014708 A MX2014014708 A MX 2014014708A MX 2014014708 A MX2014014708 A MX 2014014708A MX 2014014708 A MX2014014708 A MX 2014014708A MX 2014014708 A MX2014014708 A MX 2014014708A
Authority
MX
Mexico
Prior art keywords
compounds
thiophenylamide
new bicyclic
bicyclic
new
Prior art date
Application number
MX2014014708A
Other languages
English (en)
Inventor
Werner Neidhart
Bernd Kuhn
Simona M Ceccarelli
Hans Richter
Ulrike Obst Sander
Holger Kuehne
Bernd Buettelmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014014708A publication Critical patent/MX2014014708A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención proporciona nuevos compuestos de la fórmula general (I) (ver Fórmula) en la que R1, R2, R3, R4, R5, R6, R7, A, E y n tienen los significados aquí definidos, composiciones que incluyen los compuestos y métodos de uso de los compuestos.
MX2014014708A 2012-06-19 2013-06-14 Nuevos compuestos biciclicos de tiofenilamida. MX2014014708A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12172528 2012-06-19
PCT/EP2013/062314 WO2013189841A1 (en) 2012-06-19 2013-06-14 New bicyclic thiophenylamide compounds

Publications (1)

Publication Number Publication Date
MX2014014708A true MX2014014708A (es) 2015-02-24

Family

ID=48626047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014708A MX2014014708A (es) 2012-06-19 2013-06-14 Nuevos compuestos biciclicos de tiofenilamida.

Country Status (13)

Country Link
US (1) US9604977B2 (es)
EP (1) EP2861574B1 (es)
JP (1) JP6215924B2 (es)
KR (1) KR20150023804A (es)
CN (1) CN104395301B (es)
AR (1) AR091464A1 (es)
BR (1) BR112014030474A2 (es)
CA (1) CA2869232A1 (es)
ES (1) ES2577306T3 (es)
MX (1) MX2014014708A (es)
RU (1) RU2644565C2 (es)
TW (1) TW201402560A (es)
WO (1) WO2013189841A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104693169A (zh) * 2015-02-11 2015-06-10 佛山市赛维斯医药科技有限公司 一种硝基取代的甲氧苯噻吩酰胺类双靶点抑制剂及其用途
CN104803946A (zh) * 2015-03-03 2015-07-29 佛山市赛维斯医药科技有限公司 含腈基噻唑和环戊二烯结构的ptp1b抑制剂及其用途
US11147790B2 (en) 2017-06-06 2021-10-19 Verrica Pharmaceuticals Inc. Treatment of cutaneous disorders
CA3066079C (en) 2017-06-15 2025-09-02 Verrica Pharmaceuticals Inc. DEVICES AND METHODS FOR THE TREATMENT OF BODY SURFACE CONDITIONS
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
BR112020006703A2 (pt) 2017-10-04 2020-10-06 Verrica Pharmaceuticals, Inc. síntese de cantaridina
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
CN109884212A (zh) * 2019-03-27 2019-06-14 清华大学深圳研究生院 基于化学衍生化与hplc-ms的不饱和脂肪酸定量方法
BR112022026550A2 (pt) 2020-06-27 2023-01-17 Crescenta Biosciences Composição de compostos que modulam o metabolismo celular e métodos de uso
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds
CN115636724A (zh) * 2022-10-18 2023-01-24 浙大宁波理工学院 一种4-氟-4-甲基环己醇及其制备方法
WO2024254161A2 (en) * 2023-06-05 2024-12-12 Celloram Inc. Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making
WO2025226670A1 (en) * 2024-04-23 2025-10-30 Celloram, Inc. Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275962A1 (en) * 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7772232B2 (en) * 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
US7998974B2 (en) * 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
EP1937663A1 (en) * 2005-09-29 2008-07-02 Inpharmatica Limited Thiophene derivatives as ppar agonists i
JP5232144B2 (ja) * 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ

Also Published As

Publication number Publication date
RU2014152350A (ru) 2016-08-10
BR112014030474A2 (pt) 2017-06-27
RU2644565C2 (ru) 2018-02-13
JP6215924B2 (ja) 2017-10-18
CA2869232A1 (en) 2013-12-27
HK1206340A1 (en) 2016-01-08
US20150175594A1 (en) 2015-06-25
CN104395301A (zh) 2015-03-04
ES2577306T3 (es) 2016-07-14
KR20150023804A (ko) 2015-03-05
AR091464A1 (es) 2015-02-04
CN104395301B (zh) 2017-07-28
WO2013189841A1 (en) 2013-12-27
EP2861574B1 (en) 2016-04-20
EP2861574A1 (en) 2015-04-22
JP2015520199A (ja) 2015-07-16
US9604977B2 (en) 2017-03-28
TW201402560A (zh) 2014-01-16

Similar Documents

Publication Publication Date Title
MX2014014708A (es) Nuevos compuestos biciclicos de tiofenilamida.
IN2014DN09346A (es)
IN2015DN00960A (es)
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
PH12014500814A1 (en) New aryl-quinoline derivatives
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
PH12014502397B1 (en) Pesticidal compositions and processes related thereto
MX2015008072A (es) Composiciones plaguicidas y los procedimientos relacionados con las mismas.
PH12014500930A1 (en) Pesticidal compositions and processes related thereto
PH12014500910A1 (en) Pesticidal compositions and processes related thereto
PH12013502686A1 (en) Pesticidal compositions and processes related thereto
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
PH12013502434A1 (en) Substituted pyridopyrazines as novel syk inhibitors
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
PH12015501038A1 (en) Inhibitors of iap
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.